Clinical Research Directory
Browse clinical research sites, groups, and studies.
Retrospective Observational Multicenter Study on the Treatment Patterns, Extra-Intestinal Manifestations, Resource Utilisation, and Outcomes of Patients With Inflammatory Bowel Disease in Dutch Hospitals
Sponsor: LOGEX
Summary
This multicenter retrospective real-world data study will evaluate the treatment pathways and disease burden of adult patients with Crohn's disease (CD) and ulcerative colitis (UC) treated in 5-10 Dutch hospitals between 2018 and 2026. The study will assess: * Treatment sequences, switching patterns, and treatment duration * Prevalence and incidence of extra-intestinal manifestations (EIMs) * Healthcare resource utilization (hospitalizations, outpatient visits, endoscopies, surgery, and length of stay) * Direct healthcare costs * Availability of disease activity biomarkers Using linked administrative, prescription, procedure, and laboratory data, outcomes will be analyzed by age, line of therapy, and clinical characteristics. Special focus will be placed on the impact of EIMs on treatment patterns, healthcare utilization, and costs. The findings will provide real-world evidence on IBD management in the Netherlands and support clinical decision-making, healthcare planning, and future research on treatment optimization and coexisting immune-mediated conditions.
Official title: Treatment Patterns, Extra-Intestinal Manifestations, Resource Utilisation, and Outcomes of Patients With Inflammatory Bowel Disease in Dutch Hospitals
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
3500
Start Date
2026-08-01
Completion Date
2027-06-30
Last Updated
2026-07-02
Healthy Volunteers
No
Interventions
Routine hospital care data (observational)
This is a non-interventional, retrospective observational study. No intervention is administered as part of this study. The study observes and analyses routinely collected hospital data on existing treatment patterns for Crohn's disease and ulcerative colitis, including conventional therapies and advanced systemic treatments (biologics, JAK inhibitors, S1P modulators), as prescribed in routine clinical care.